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Abstract
Abdominal aortic aneurysms (AAAs) are expansions in the aortic wall with an increased
tendency to rupture. These expansions are triggered by the breakdown of key aortic extracellular
matrix (ECM) proteins—elastin and collagen. The degradation of aortic ECM proteins is the
consequence of overexpressed matrix metalloproteases (MMPs)–MMP-2 and MMP-9. Adult
vascular smooth muscle cells (SMCs) lack the ability to repair the elastic matrix assembly; thus,
it is imperative to find a solution to both restore the imbalance of essential ECM proteins in the
aorta and mitigate the effects of MMPs. Previous studies have revealed that bone marrow
derived mesenchymal stem cells (BM-MSCs) differentiated into smooth muscle-like cells
(SMLCs) have the ability to induce elastic matrix assembly and reduce MMP-9 activity in
aneurysmal rat aortic SMCs. The purpose of this study was to determine an optimal means to
differentiate human BM-MSCs (hBM-MSCs) into SMLCs in order study these effects
efficiently. Based on previous research, hBM-MSCs were plated onto fibronectin coated flasks
and treated for four days with the following: differentiation medium (DM), DM with all-trans
retinoic acid (atRA), DM with platelet-derived growth factor-BB (PDGF), and DM
supplemented with both PDGF and transforming growth factor-β1 (TGF-β1). Western blot
analysis revealed that untreated hBM-MSCs exhibit early and mid-stage SMC markers, SM22-α
and caldesmon, but miniscule amounts of late-stage SMC marker, smooth muscle myosin heavy
chain-11 (MYH11). Analysis also determined that treatment supplemented with both PDGF and
TGF-β1 resulted in the highest expression of MYH11 and the least expression in stem cell
marker, CD44.
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Introduction
Abdominal Aortic Aneurysms (AAAs)
Abdominal aortic aneurysms (AAAs) are characterized as localized expansions in the
abdominal aorta with the propensity to rupture [1]. AAA is estimated to affect 1.1 million
Americans aged 50-84 [2]. In 2017 alone, the Centers for Disease Control and Prevention
documented 9,928 deaths caused by aortic aneurysm in the United States of America [3]. Age
and smoking have been identified as key risk factors for AAA with an increase in AAA
prevalence in males over females [2]. Currently, AAAs deemed subcritical in size—below 5.5
cm in diameter—have no treatment while surgical procedure is the predominant treatment for
AAAs considered critical—above 5.5 cm in diameter [1]. With the prevalence of AAA
increasing with age, there is a strong need for a non-surgical and minimally invasive treatment
option for AAA.
AAA is caused by the breakdown in structural matrix proteins [1]. The aortic
extracellular matrix (ECM) is primarily composed of elastin and collagen [4]. With elastin
contributing approximately 50% and collagen 20% to the aortic ECM [5], these two proteins
elicit the vital properties of strength and flexibility essential for holding arterial blood pressure
[4]. An imbalance in the synthesis and degradation of ECM proteins is evident in aortic
aneurysms with chronic inflammation attributing to ECM degradation [4]. The breakdown in
aortic ECM proteins is a result of the overexpression in matrix metalloproteases, MMPs,
specifically MMP-2 and MMP-9 [6,7]. In an animal model for thoracic aortic aneurysms, Mao,
et al. revealed a connection between the increased expression of MMPs-2 and -9 and a
phenotypic switch in vascular smooth muscle cells to a diseased state [8]. Furthermore,
elastogenesis is primarily restricted to early development with little elastogenesis in adults [5].
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Consequently, adult vascular smooth muscle cells exhibit a poor ability to repair the elastic
matrix assembly [1,9]. Therefore, in order to achieve stagnation and recession of AAAs, it is
essential to inhibit MMP-mediated degradation and restore the balance of ECM proteins in the
aortic wall.
Human Bone Marrow Derived Mesenchymal Stem Cells (hBM-MSCs)
Mesenchymal stem cells (MSCs) offer an autologous source of cells exhibiting
multipotency illustrated by the ability to differentiate into multiple cell types such as: osteoblasts,
adipocytes, and chondrocytes [4]. Furthermore, MSCs derived from bone marrow (BM-MSCs)
have shown the ability to differentiate into a smooth muscle-like state [10,11,12,13]. Previous
studies have demonstrated that rat BM-MSCs differentiated into smooth muscle-like cells
(SMLCs) exhibit a higher elastogenic potential over adult vascular smooth muscle cells (SMCs)
[13]. In a co-culture with aneurysmal rat aortic SMCs (EaRASMCs), the SMLCs stimulated
elastic matrix assembly in the EaRASMCs through the use of paracrine signaling [13].
Additionally, the SMLCs repressed elastolytic MMP-9 activity in the EaRASMCs [13].
Therefore, an effective means of differentiating human BM-MSCs (hBM-MSCs) into
SMLCs is vital in order to efficiently study the benefits provided by SMLCs in relation to AAA.
Recent studies have revealed numerous approaches to the differentiation of hBM-MSCs into
SMLCs. Treatment of hBM-MSCs with all-trans retinoic acid (atRA) [10], platelet-derived
growth factor with two B subunits (PDGF) [11], and PDGF in tandem with transforming growth
factor-β1 (TGF-β1) [12,13] have shown successful differentiation into SMLCs. The purpose of
this study is to evaluate the ability of the above treatments to effectively differentiate hBMMSCs into SMLCs based on phenotype assessed via western blot.
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Materials and Methods
Cell Culture
hBM-MSCs were purchased from American Type Culture Collection (ATCC). The cells
were cultured at 37˚C and 5% CO2 in ATCC basal stem cell medium (ATCC, PCS-500-030)
supplemented with an ATCC hBM-MSC growth kit (ATCC, PCS-500-041) containing 2.4 mM
L-Alanyl-L-Glutamine, 7% fetal bovine serum (FBS), 15 ng/mL recombinant human insulin-like
growth factor-1, and 5 ng/mL recombinant human fibroblast growth factor-b. Medium was
changed every 2-3 days, and cell passage was conducted at approximately 80% confluence.
Human aortic smooth muscle cells (hASMCs, Cell Applications) were cultured in human smooth
muscle cell growth medium (Cell Applications) and used as a positive control for SMC markers.
Cell Treatment
As previously reported in detail by Swaminathan et al. [13], hBM-MSCs were counted
via hemocytometer (Reichert) and plated onto 100 ng/mL human fibronectin (Gibco) coated
T175 flasks (VWR) at a cell density of 2000 cells/cm2. Cell density was purposefully low to
mitigate cell-to-cell interaction. Plated cells were treated for 4 days with the following
treatments: differentiation medium (DM) containing 60% v/v DMEM, low glucose, pyruvate
(Gibco), 40% v/v MCDB-201 (Sigma-Aldrich), 1% v/v antibiotic/antimycotic (Gibco), 1x
insulin-transferrin-selenium (Gibco), 1x linoleic acid – albumin from bovine serum albumin
(Sigma-Aldrich), 10-9M dexamethasone (Sigma-Aldrich), 10-4M ascorbic acid (Sigma-Aldrich),
10 ng/mL human epidermal growth factor (Sigma-Aldrich), and 103 U/mL human leukemia
inhibitory factor (Sigma-Aldrich), DM supplemented with 50 µM atRA (Abcam), DM
supplemented with 10 µg/mL human PDGF (Sigma-Aldrich), and DM supplemented with 10
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µg/mL human PDGF (Sigma-Aldrich) and 2.5 ng/mL human TGF-β1 (Millipore). Medium was
changed every 2-3 days.
Cell Harvesting
Following treatment, cell medium was aspirated and the flasks were washed twice with
phosphate-buffered saline (PBS, Hyclone). Cells were detached using trypsin-EDTA (ATCC).
Cells were incubated in trypsin-EDTA at 37˚C for five minutes. Detached cells were added to a
conical vial and trypsin-neutralizing solution (ATCC) was applied. Cells were centrifuged at
1000 x g for five minutes. The cell pellet was washed two times with ice-cold PBS. Pierce RIPA
lysis buffer (Thermo Scientific) containing Halt protease inhibitor cocktail (Thermo Scientific)
was used to lyse the cells. Cell lysates were sonicated (Misonix Ultrasonic Liquid Processor) at a
50% pulse for 30 seconds and centrifuged at 14,000 x g for 5 minutes. The supernatant was
collected and frozen at -80˚C for further experimentation.
BCA Protein Assay
A bicinchoninic acid (BCA) protein assay (Thermo Scientific) was used to quantify the
protein concentrations from each sample. Samples were diluted ten-fold with Pierce RIPA lysis
buffer (Thermo Scientific). Standards were created at the following concentrations using bovine
serum albumin (Thermo Scientific): 2000, 1500, 1000, 750, 500, 250, 125, 25, and 0 µg/mL.
RIPA lysis buffer (Thermo Scientific) was used as the diluent for the protein standards. A 25 µL
aliquot of each standard and diluted sample was added in duplicate to a 96-well microplate, and
200 µL of Pierce BCA protein assay reagent mix (Thermo Scientific) was added to each standard
and sample. The microplate was covered and incubated for 30 minutes at 37°C. Using a BioTek
Synergy 2 plate spectrophotometer and BioTek Gen5 software, the absorbance at 562nm was
measured for both the standards and the samples. The absorbance values and the known
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concentration of the standards were used in Microsoft Excel to generate a quadratic regression.
This standard curve was then used to evaluate the unknown protein concentration of the samples.
Western Blotting
Sample Preparation
Due to low protein concentration, the amount of each sample collected for the western
blot assay was standardized to 6-8 µg of protein depending on the trial. Samples were mixed with
2x Laemmli sample buffer (Bio-Rad) containing 2-mercaptoethanol (Aldrich Chemistry) at a 1:1
ratio and vortexed. The samples were then boiled at 95°C for 5 minutes using a water bath and
vortexed once more. The samples were centrifuged at 16,000 x g for 1 minute.
Gel Electrophoresis
A 4–20% Mini-PROTEAN TGX Stain-Free protein gel (Bio Rad) was prepared with
Tris/glycine/sodium dodecyl sulfate (SDS) buffer (Bio-Rad, 25mM Tris, 192 mM glycine, 0.1%
SDS) for gel electrophoresis. The gel was loaded with Precision Plus Protein WesternC standard
(Bio-Rad) and samples equilibrated for total protein content. The gel was then electrophoresed
with a Mini-PROTEAN Tetra System (Bio-Rad) and PowerPac Basic (Bio-Rad).
Transfer
Following electrophoresis, proteins were transferred onto polyvinylidene difluoride
(PVDF) membrane (Bio-Rad, Trans-Blot Turbo Transfer Pack) using a Trans-Blot Turbo
Transfer System (Bio-Rad). After transfer, the membrane was submerged in SuperBlock
blocking buffer (Thermo Scientific) for one hour at room temperature.
Blotting
Depending on recommended protocol by manufacturer, primary antibodies were either
incubated at room temperature for 1 hour or overnight at 4˚C. Primary antibodies include: stem
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cell marker CD44 (R&D Systems), early-stage SMC marker SM22-α (Abcam), mid-stage SMC
marker caldesmon (Sigma-Aldrich), late-stage SMC marker smooth muscle myosin heavy chain11 (MYH11, Abcam), and loading control β-actin (Sigma-Aldrich). After primary antibody
incubation, the membrane was washed 3x for 5 minutes in Tris-buffered saline (Bio-Rad) with
0.1% Tween-20, TBST (Fisher Scientific). Following the washes, respective horse-radishperoxidase-conjugated secondary antibody was applied to the membrane. Secondary antibodies
include: goat anti-rabbit IgG (Abcam), rabbit anti-goat IgG (Abcam), and goat anti-mouse IgG
(Abcam).
Imaging
After three more washes with TBST, a stain-free blot image was acquired using a
ChemiDoc Imaging System (Bio-Rad). For instances in which a valid image was attained, the
stain-free blot image was used for total protein normalization. The membrane was then incubated
for five minutes in chemiluminescent substrate (Clarity or Clarity Max Western ECL Blotting
Substrate, Bio-Rad). Chemiluminescent blot images were captured using a ChemiDoc Imaging
System (Bio-Rad).
Blot Stripping
Blot antibodies were removed by applying a low pH stripping buffer (0.20 M glycine,
3.47 mM SDS, 1% Tween-20, pH 2.2) twice for 10 minutes each. The membrane was then
washed 2x with PBS (Hyclone) for 10 minutes followed by two TBST washes for 5 minutes. The
membrane was then blocked and reprobed with antibody as necessary.
Protein Normalization
Utilizing Image Lab software (Bio-Rad), blot pixel intensity for each protein band of
interest was quantified and normalized to the stain-free blot image. For the instances in which a
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stain-free blot image was incompetent, blots were stripped and reprobed for the housekeeping
protein, β-actin, and subsequently normalized to β-actin.
Replicates
For SM22-α and CD44, biological duplicates were performed beginning with cell
treatment. Thus, each trial originated from a different cell lysate and was performed on a
separate gel and blot. For caldesmon and MYH11, technical duplicates were performed
originating from the same cell lysates and executed on separate gels and blots.
Data Analysis
To perform statistical analysis, the fold change was calculated based on the normalized
intensity of each treatment with respect to either the hASMCs or the DM treatment depending on
trial. For CD44, the fold change was relative to the DM treatment. For SMC markers, the fold
change was relative to the hASMCs. A two-sample equal variance t-test with two tails was used
to test for significance between treatment and control. P-values less than 0.05 were regarded as
significant and denoted by *. P-values less than 0.01 were denoted by **.

Results
Smooth muscle cell characterization of untreated hBM-MSCs and treated hBM-MSCs
Untreated hBM-MSCs and hASMCs were harvested and characterized via Western blot.
Treated hBM-MSCs were plated onto fibronectin coated T175 dishes at a low cell density (2,000
cells/cm2). For four days, plated hBM-MSCs were treated with differentiation medium, DM, (see
above for components), DM supplemented with all-trans retinoic acid (atRA), DM supplemented
with platelet-derived growth factor-BB (PDGF) and DM supplemented with PDGF and
transforming growth factor-β1 (TGF-β1). Treatments were harvested, and the SMC phenotype
was determined via Western blot. Blots were probed with SMC markers: early-stage marker,
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SM22-α, mid-stage marker, caldesmon, and late-stage marker, smooth muscle myosin heavy
chain-11 (MYH11) (Figure 1-A). Protein bands were normalized to respective stain-free blot
images or β-actin bands using Image Lab. Fold change was calculated with respect to hASMCs
(Figure 1-B). Western blot analysis revealed that hBM-MSCs in basal stem cell medium display
early and mid-stage SMC protein markers, SM22-α (n = 1) and caldesmon (n = 2), at levels
comparable to that of hASMCs (Figure 1). However, hBM-MSCs exhibit significantly less
expression of late-stage marker, smooth muscle myosin heavy chain-11 (MYH11, n = 2),
compared to hASMCs with a p-value < 0.01 (Figure 1). For treated hBM-MSCs, the treatment
supplemented with PDGF and TGF-β1 showed a statistically significant increase in MYH11
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Figure 1: hASMCs and hBM-MSCs were cultured in, respectively, human SMC growth medium and
basal stem cell medium supplemented with a growth kit specific to hBM-MSCs. Treated hBM-MSCs were
plated onto fibronectin coated T175 flasks and treated for 4 days with DM, DM + atRA, DM + PDGF,
and DM + PDGF + TGF-β1. Western blot analysis was performed for SMC markers (A): SM22-α,
caldesmon, and smooth muscle myosin heavy chain-11 (MYH11) and normalized to β-actin or stain-free
image (not shown). Duplicates were performed for all trials except for SM22-α on hBM-MSCs. Fold
change was determined with respect to hASMCs (B). hBM-MSCs exhibit significantly less expression of
MYH11 compared to hASMCs (p-value < 0.01) (B). The treatment supplemented with PDGF and TGF-β1
(DM + PDGF + TGF-β1) showed a statistically significant increase in MYH11 expression (B) with a pvalue < 0.05.

Stem cell marker characterization of treated hBM-MSCs
hBM-MSCs were treated for four days as stated previously. Western blot analysis was
conducted to measure the expression of stem cell marker: CD44 (Figure 2-A). Fold change was
analyzed with respect to DM treatment (Figure 2-A). The treatment containing DM
supplemented with PDGF and TGF-β1 showed a statistically significant decrease in CD44
(Figure 2-B) with p-value < 0.05 when compared to the DM treatment with no additives. The
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DM treatment supplemented with PDGF showed a significant increase in CD44 expression with
a p-value < 0.05 (Figure 2-B).
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Figure 2: Treated hBM-MSCs were plated onto fibronectin coated T175 flasks and treated for 4 days
with DM, DM + atRA, DM + PDGF, and DM + PDGF + TGF-β1. Western blot analysis was performed
for stem cell marker: CD44 (A) and normalized to β-actin or stain-free image (not shown). Duplicates
were performed for all trials except for hBM-MSCs. Fold change was determined with respect to DM
treatment (B). The treatment supplemented with PDGF and TGF-β1 (DM + PDGF + TGF-β1) showed a
statistically significant decrease in CD44 expression when compared to DM (p-value < 0.05) (B). The
treatment supplemented with PDGF (DM + PDGF) showed a significant increase in CD44 expression
when compared to DM (p-value < 0.05) (B).
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Discussion and Conclusions
Abdominal aortic aneurysms are caused by the breakdown in extracellular matrix
proteins—elastin and collagen [1,4]. This breakdown is mediated by the overexpression of
MMP-2 and MMP-9 [6,7]. Furthermore, adult vascular smooth muscle cells (SMCs) exhibit
minimal elastogenesis to facilitate the repair of the elastic matrix [1,5,9]. While adult vascular
SMCs display poor elastogenic potential, bone marrow derived mesenchymal stem cells (BMMSCs) offer a promising source of autologous cells with a high elastogenic potential [13]. BMMSCs differentiated into smooth muscle-like cells (SMLCs) have demonstrated a higher
elastogenic potential over adult vascular SMCs [13]. When co-cultured with aneurysmal rat
aortic SMCs (EaRASMCs), these SMLCs have been shown to stimulate the elastic matrix
assembly and reduce the MMP-9 activity in the EaRASMCs through paracrine signaling [13]. To
effectively study this impact, an efficient means to differentiate BM-MSCs is essential. In this
study, three different treatments—all-trans retinoic acid (atRA) [10], platelet-derived growth
factor-BB (PDGF) [11], and PDGF with transforming growth factor-β1 (TGF-β1) [12,13]—
previously shown to differentiate BM-MSCs into SMLCs were investigated.
Through the use of Western blot analysis, the SMC differentiation state after four days of
treatment of human BM-MSCs (hBM-MSCs) was examined. SMC markers analyzed include:
early-stage, SM22-α, mid-stage, caldesmon, and late-stage, smooth muscle myosin heavy chain11 (MYH11). Expression of stem cell marker, CD44, was also evaluated. hBM-MSC basal
expression of SMC markers was compared to that of human aortic SMCs (hASMCs) and shown
to express SM22-α and caldesmon at levels similar to that of hASMCs (Figure 1). However,
hBM-MSCs basal expression of the late-stage marker, MYH11, was significantly less to that of
hASMCs (Figure 1). This evaluation is congruent with that shown by Tamama et al. in which
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untreated hBM-MSCs expressed early and mid-stage SMC markers, α-smooth muscle actin and
caldesmon, with minimal expression of smooth muscle myosin heavy chain [14]. Therefore, it is
critical for further studies to include late-stage SMC markers in the evaluation of hBM-MSC
differentiation into SMLCs.
In further Western blot analysis, treatment with differentiation medium (DM)
supplemented with PDGF and TGF-β1 showed a statistically significant increase in MYH11
expression and a significant decrease in CD44 expression over treatment without
supplementation. Treatment with DM supplemented with PDGF revealed an increase in CD44
expression. Based on these results, treatment of hBM-MSCs with DM containing PDGF in
tandem with TGF-β1 provides the most efficient means of SMC differentiation. However, since
trial count is low (n = 2), further study is required.
Future work should incorporate multiple methods of characterizing the SMC
differentiation state of hBM-MSCs such as: flow cytometry, immunohistochemistry, and reverse
transcriptase polymerase chain reaction (RT-PCR). Furthermore, seven-day experimentation will
offer insight into the effects regarding the length of each treatment.
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